W
William Petkun
Researcher at Bristol-Myers Squibb
Publications - 5
Citations - 1077
William Petkun is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Warfarin & Atrial fibrillation. The author has an hindex of 5, co-authored 5 publications receiving 844 citations. Previous affiliations of William Petkun include Harvard University.
Papers
More filters
Journal ArticleDOI
Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population
TL;DR: It can be concluded that both incidence and prevalence of AF are likely to rise from 2010 to 2030, but there exists a wide range of uncertainty around the magnitude of future trends.
Journal ArticleDOI
Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban.
Ping G. Tepper,Jack Mardekian,Cristina Masseria,Hemant Phatak,Shital Kamble,Younos Abdulsattar,William Petkun,Gregory Y.H. Lip +7 more
TL;DR: NVAF patients treated with rivaroxaban appeared to have an increased risk of any bleeding, CRNM bleeding, and major inpatient bleeding, compared to apixaban patients, and dabigatran patients had similar bleeding risks.
Journal ArticleDOI
Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial.
Michael D. Ezekowitz,Michael D. Ezekowitz,Charles V. Pollack,Paul Sanders,Jonathan L. Halperin,Judith Spahr,Nilo B. Cater,William Petkun,Andrei Breazna,Paulus Kirchhof,Jonas Oldgren +10 more
TL;DR: This first prospective cardioversion study of a novel anticoagulation-naïve patients with atrial fibrillation undergoing cardioversion comparing apixaban to heparin plus warfarin should influence clinical practice.
Journal ArticleDOI
Ischemic Stroke in Nonvalvular Atrial Fibrillation at Warfarin Initiation: Assessment via a Large Insurance Database.
Ping G. Tepper,X. Liu,Melissa Hamilton,Jack Mardekian,William Petkun,Wilson Tan,Daniel E. Singer +6 more
TL;DR: Warfarin effect was qualitatively different in the first 30 days after initiation than subsequently, consistent with a modest increase in stroke risk occurring briefly after starting warfarin.
Journal ArticleDOI
Abstract 206: Projected Estimates of Prevalence and Annual Growth Rate of Atrial Fibrillation in the United States from a Dynamic Age-Period Progression Model
TL;DR: These estimates, derived from the largest longitudinal study sample reported thus far, with a dynamic age-period cohort progression model, suggest that the diagnosed AF population in the US in 2010 was approximately 5.2 million cases, which falls within the wide range previously reported in the literature and may represent a more precise estimate.